Simcere Pharmaceutical Group Limited (Simcere, Stock code: 2096) announced the signing of a license agreement with Vigonvita Life Science Co., Ltd. (Vigonvita, 2630.HK) on December 3, 2025, involving new indications for Deuterated Remdesivir Hydrobromide in the Greater China region. The treatment targets respiratory syncytial virus (RSV) infection and human metapneumovirus (HMPV) infection.

Deuterated Remdesivir Hydrobromide is an oral nucleoside antiviral candidate that inhibits viral RNA-dependent RNA polymerase (RdRp). A Phase II clinical trial in China examining the therapy in infants and young children aged 1–24 months for RSV infection has concluded, demonstrating favorable antiviral efficacy and a good safety profile. As a result, the dry suspension formulation received Breakthrough Therapy designation from the Center for Drug Evaluation of the National Medical Products Administration. In addition, the tablet formulation previously garnered full approval in China for the treatment of mild-to-moderate COVID-19 in adults.

Vigonvita focuses on developing novel drugs in neuropsychiatry, reproductive health, and viral infections. Simcere, an R&D-driven pharmaceutical group, aims to strengthen its anti-infection product portfolio through this new collaboration, supported by its in-house research and collaborations with innovative partners.